137 related articles for article (PubMed ID: 2301374)
21. 8;21 translocation in myelodysplasia secondary to essential thrombocythemia.
Knottenbelt E; Hallett J; Jacobs P
Am J Hematol; 1989 Apr; 30(4):233-5. PubMed ID: 2929582
[TBL] [Abstract][Full Text] [Related]
22. Nail changes after chemotherapy.
Las Heras G; Juncà Piera J
Haematologica; 1998 Aug; 83(8):748. PubMed ID: 9793260
[No Abstract] [Full Text] [Related]
23. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
24. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic transformation in a case of essential thrombocythemia treated with pipobroman.
Messora C; Bensi L; Vanzanelli P; Temperani P; Carotenuto M; Sacchi S
Haematologica; 1996; 81(1):51-3. PubMed ID: 8900853
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
Finazzi G; Ruggeri M; Rodeghiero F; Barbui T
Blood; 2003 May; 101(9):3749. PubMed ID: 12707224
[No Abstract] [Full Text] [Related]
27. Multiple myeloma following essential thrombocythemia.
Ben Youssef Y; Gmidène A; Bouabid Z; Bouallegui S; Sriha B; Zaier M; Sennana H; Khelif A
Ann Biol Clin (Paris); 2013; 71(4):457-60. PubMed ID: 23906574
[TBL] [Abstract][Full Text] [Related]
28. A novel t(2;17) in transformation of essential thrombocythemia to acute myelocytic leukemia.
Lazarevic VLj; Tomin D; Jankovic GM; Antic D; Dencic M; Gotic M; Boskovic D
Cancer Genet Cytogenet; 2004 Jan; 148(1):77-9. PubMed ID: 14697645
[TBL] [Abstract][Full Text] [Related]
29. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
Passamonti F; Cazzola M
Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
[No Abstract] [Full Text] [Related]
30. Essential thrombocythemia transforming into acute biphenotypic leukemia in a patient on hydroxyurea monotherapy.
Sandhu G; Ranade A; Siddiqi S; Balderacchi JL
Ann Oncol; 2009 Nov; 20(11):1899-900. PubMed ID: 19752004
[No Abstract] [Full Text] [Related]
31. Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.
Tefferi A; Passamonti F
Am J Hematol; 2009 Oct; 84(10):629-30. PubMed ID: 19731306
[No Abstract] [Full Text] [Related]
32. Hydroxyurea as a cause of drug fever.
Braester A; Quitt M
Acta Haematol; 2000; 104(1):50-1. PubMed ID: 11111124
[TBL] [Abstract][Full Text] [Related]
33. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C
Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360
[TBL] [Abstract][Full Text] [Related]
34. Essential thrombocythemia and acute leukemia.
Ferrari D; Ticozzelli G; De Vizzi M; Corigliano P; De Vizzi G
Haematologica; 1993; 78(6):401-2. PubMed ID: 8175035
[TBL] [Abstract][Full Text] [Related]
35. Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan.
Candoni A; Tiribelli M; Fanin R
Leuk Lymphoma; 2004 Apr; 45(4):821-4. PubMed ID: 15160964
[TBL] [Abstract][Full Text] [Related]
36. Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
Bain BJ; Garnett C; Deplano S; Naresh K; Kanfer E
Am J Hematol; 2013 May; 88(5):426. PubMed ID: 23460316
[No Abstract] [Full Text] [Related]
37. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
Samuelson B; Chai-Adisaksopha C; Garcia D
J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
[TBL] [Abstract][Full Text] [Related]
38. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
[TBL] [Abstract][Full Text] [Related]
39. [A lower-leg ulcer during hydroxyurea therapy for essential thrombocythemia].
Iwama H; Kawakubo K; Nehashi Y; Kuriyama Y; Iwase O; Ohyashiki K; Watanabe K; Ebihara Y; Toyama K
Gan To Kagaku Ryoho; 1996 Jun; 23(7):937-9. PubMed ID: 8678547
[TBL] [Abstract][Full Text] [Related]
40. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
